Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tiragolumab + atezolizumab + chemotherapy vs pembrolizumab + chemotherapy in advanced non-squamous NSCLC
CTR20222734Phase 3Terminated
- Sponsor
- Roche
- Start
- Oct 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of tiragolumab in Non-small cell lung cancer (NS-NSCLC), sponsored by Roche. Started Oct 2022; status: terminated.
02
Drugs
tiragolumab
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on CTR20222734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222734.